共 112 条
[1]
Chung JC(2016)Limited resection for duodenal gastrointestinal stromal tumors and their oncologic outcomes Surg Today 46 110-116
[2]
Kim HC(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-480
[3]
Hur SM(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338
[4]
Demetri GD(2013)Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 295-302
[5]
von Mehren M(2015)Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS) Ann Surg Oncol 22 2948-2957
[6]
Blanke CD(2007)Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST Ann Surg 245 341-346
[7]
Van den Abbeele AD(2012)Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors J Surg Res 177 248-254
[8]
Eisenberg B(2014)A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors Cardiovasc Intervent Radiol 37 132-139
[9]
Roberts PJ(2015)Management of liver metastases of gastrointestinal stromal tumors (GIST) Ann Hepatol. 14 531-539
[10]
Demetri GD(2014)Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China Eur J Cancer 50 1772-1778